Search results
Results from the WOW.Com Content Network
Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), P-30 antigen, is a glycoprotein enzyme encoded in humans by the KLK3 gene.PSA is a member of the kallikrein-related peptidase family and is secreted by the epithelial cells of the prostate gland in men and the paraurethral glands in women.
Prostate cancer screening is the screening process used to detect undiagnosed prostate cancer in men without signs or symptoms. [1] [2] When abnormal prostate tissue or cancer is found early, it may be easier to treat and cure, but it is unclear if early detection reduces mortality rates.
From the AJCC 7th edition [5] and UICC 7th edition. [6]Stage I disease is cancer that is found incidentally in a small part of the sample when prostate tissue is removed for other reasons, such as benign prostatic hyperplasia, and the cells closely resemble normal cells and the gland feels normal to the examining finger.
The Gleason grading system is used to help evaluate the prognosis of men with prostate cancer using samples from a prostate biopsy.Together with other parameters, it is incorporated into a strategy of prostate cancer staging which predicts prognosis and helps guide therapy.
Andrew Julian Vickers (born 11 February 1967) [1] [2] is a biostatistician and attending research methodologist at Memorial Sloan Kettering Cancer Center. Since 2013, he has also been professor of public health at Weill Cornell Medical College. [3] He is the statistical editor for the peer-reviewed journal European Urology. [4]
Prostate cancer is the uncontrolled growth of cells in the prostate, a gland in the male reproductive system below the bladder.Abnormal growth of prostate tissue is usually detected through screening tests, typically blood tests that check for prostate-specific antigen (PSA) levels.
Recognizing that these men differ from those diagnosed today with PSA screening, the cumulative incidence of death from prostate cancer was 20.7% in the untreated group overall, and 11% for men with low risk disease (PSA below 10 ng/ml and Gleason score below 7) - similar to the cumulative incidence of death from prostate cancer of 12.3% at 30 ...
PFS is widely used as a surrogate endpoint in oncology. [4] The definition of "progression" generally involves imaging techniques (plain radiograms, CT scans, MRI, PET scans, ultrasounds) or other aspects: biochemical progression may be defined on the basis of an increase in a tumor marker (such as CA125 for epithelial ovarian cancer or PSA for prostate cancer).